Skip to Content

'
Banu Arun, MD

Present Title & Affiliation

Primary Appointment

Professor (Tenure), Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor (Tenure), Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Dr. Banu Arun is a Professor in the Department of Breast Medical Oncology at MD Anderson Cancer Center.  Dr. Arun is also Co-Medical Director of the Clinical Cancer Genetics Program at MD Anderson Cancer Center.   Her research interests include breast cancer, biological markers, chemoprevention, and breast cancer genetics.  Her laboratory and clinical research include characterization of risk factors in high-risk women with or without deleterious BRCA mutations and assessing breast cancer biology in patients with breast cancer who have mutations of the BRCA1 or BRCA2 gene.  Dr. Arun has served as the Principal Investigator of several phase II breast cancer prevention trials with agents such as celecoxib, atorvastatin and targretin, and also breast cancer trials with PARP inhibitors.  Dr.  Arun serves as an ASCO Cancer Prevention and ASCO Genetics Subcommittee member as well as an NCCN breast cancer risk assessment committee member. Dr. Arun serves also as an SWOG Co-Chair for the Prevention Committee.  

Education & Training

Degree-Granting Education

1990 University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey, MD

Postgraduate Training

1994-1997 Fellowship, Hematology and Oncology, Vincent T. Lombardi Cancer Center Georgetown University, Washington, DC
1990-1994 Residency, Internal Medicine, University of Istanbul, Cerrahpasa Medical School, Istanbul, Turkey

Experience/Service

Academic Appointments

Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 9/2006-8/2015

Selected Publications

Peer-Reviewed Original Research Articles

1. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS; BCFR, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Andrés-Conejero R, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Douglas F, Cook J, Arun BK, ……. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 17(1):61, 2015. PMID: 25925750.
2. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Cajal TR, Nevanlinna H, Aittomäki K, Arun BK,…. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One 10(4):e0120020. doi:10.1371, 2015. PMID: 25830658.
3. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL; CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK... Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347-61, 2015. PMID: 25849179.
4. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRC2 mutations other than breast and ovarian. Cancer 121(2):269-75, 2015. PMID: 25224030.
5. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez-Garcia EB, Olopade Ol, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK,.. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 24(1):308-16, 2015. PMID: 25336561.
6. Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 23(6):770-774, 2015. PMID: 25231195.
7. Profato JL, Arun B. Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol 27(1):1-5, 2015. PMID: 25502427.
8. Bayraktar S, Gutierrez Barrera AM, Arun B, Jackson MA. Genotype-phenotype correlations by ethnicity and mutation location in BRCA mutation carriers. Breast J 21(3):260-7, 2015. PMID: 25789811.
9. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Arun B.... Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 47(2):164-71, 2015. PMID: 25581431.
10. Litton JK, Woodson AH, Peterson S, Arun B, Hortobagyi GN, Theriault RL, McKenzie L, Woodard T, Schover L, Mattair DN, Jackson M, Lin H, Muse KI, Profato J. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 2014. PMID: 24951607.
11. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer doi: 10.1002/cncr.28577, 2014. PMID: 24522996.
12. Osorio A, Milne RL, Kuchenbaecker K, Vaclova T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Diez O, Ramon Y, Cajal T, Konstantopoulou I, Martinez-Bouzas C, Andres Conejero R, Soucy P, McGuffog L, Barrowdate D, Lee A, Swe-Brca Arver B, Rantala J, Loman N, Ehrencrona H, Olopade Ol, Beauttie MS, Domcheck SM, Nathanson K, Rebbeck TR, Arun BK..., Karlan BY, Walsh C. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10(4):e1004256 doi: 10.137/journal.pgen.1004256, 2014. PMID: 24698998.
13. Ratcliff CG, Lam CY, Arun B, Valero V, Cohen L. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology 23(11):1220-8, 2014. PMID: 24706506.
14. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract. J Hum Nutr Diet doi: 10.1111/jhn.12229, 2014. PMID: 24646362.
15. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol doi: 10.1002/jso.23791, 2014. PMID: 25381882.
16. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II study of gemcitabine and vinorelbine in heavily pretreated patients with metastatic breast cancer and review of the literature. J Cancer 5(5):351-9, 2014. PMID: 24723978.
17. Elsayegh N, Kuerer HM, Lin H, Gutierrez-Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol 21(11):3466-3472, 2014. PMID: 24796968.
18. Bayraktar S, Avery T, Altundag K, Broglio K, Arun BK. Association between tumor characteristics and bone mineral density in postmenopausal breast cancer patients. Breast J 19(4):431-434, 2013. PMID: 23701522.
19. Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Establishing a program for individuals at high risk for breast cancer. J Cancer 4(5):433-446, 2013. PMID: 23833688.
20. Guan X, Liu H, Ju J, Li Y, Li P, Wang LE, Brewster AM, Buchholz TA, Arun BK, Wei Q, Liu Z. Genetic variant rs 164306bp>Obp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-hispanic white women aged <55 years. Mol Carcinog:doi: 10.1002/mc.22097, 2013. PMID: 24166930.
21. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericsen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK, SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade Ol, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmana J, Barkardottir RB, Arun BK,...CIMBA. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PloS Genet 9(3):e1003212. doi: 10.1371, 2013. PMID: 23544013.
22. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated breast cancers. Breast J 19(1):87-91, 2013. PMID: 23231005.
23. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20(4):1267-74, 2013. PMID: 23224828.
24. Bojesen SE, Arun BK..., Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collee JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Breasac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45(4):371-84, 2013. PMID: 23535731.
25. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-642, 2013. PMID: 23370825.
26. Biswas S, Arun B, Parmigiani G. Reclassification of predictions for uncovering sub-group specific improvement. Stat Med doi:10.1002/sim.6077, 2013. PMID: 24353130.
27. Biswas S, Atienza P, Chipman J, Hughes K, Gutierrez Barrera AM, Amos CI, Arun B, Parmigiani G. Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139(2):571-579, 2013. PMID: 23690142.
28. Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist 18(5):493-500, 2013. PMID: 23635555.
29. Bayraktar S, Gutierrez-Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y Symmans WF, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-17, 2013. PMID: 23337751.
30. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother 13(3):325-31, 2012. PMID: 22242911.
31. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133(1):347-55, 2012. PMID: 22270937.
32. Kuerer HM, Lari SA, Arun B, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. PMID: 22392043.
33. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19(12):3777-784, 2012. PMID: 22622473.
34. Bayraktar S, Arun B. Dose-dense chemotherapy for breast cancer. Breast J 18(3):261-6, 2012. PMID: 22583196.
35. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 2012. PMID: 21913181.
36. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2012. PMID: 21761402.
37. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):107-12, 2012. PMCID: PMC3349074.
38. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun B, Buchholz TA, Wei Q. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat 132(3):1147-55, 2012. PMID: 22218884.
39. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: Clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353-8, 2012. PMID: 22895267.
40. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blind, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res 5(9):1144-1154, 2012. PMID: 22827973.
41. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res 5(2):276-82, 2012. PMID: 22102688.
42. de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ. Tissue-based predictors of germ-line BRCA1 mutations: Implications for triaging of genetic testing. Hum Pathol 43(11):1932-1939, 2012. PMID: 22591913.
43. Ready K, Arun B, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 12/2011. e-Pub 6/2011. PMID: 21681553.
44. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun BK. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-212, 2011.
45. Roses RE, Arun B, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 18(10):2873-8, 2011. PMID: 21476105.
46. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-3907, 2011. PMID: 21365619.
47. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun B, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-1089, 2011.
48. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. PMID: 21830012.
49. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemorherapy with or withough G-CSF in locally advanced breast cancer: Long-term results. Oncologist 16(11):1527-34, 2011. PMCID: PMC3233286.
50. Bayraktar S, Elsayegh N, Gutierrez-Barerra AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstram F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2011. PMID: 22009639.
51. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 12(5):496-503, 2011. PMID: 21441069.
52. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and non-carriers: a single institution experience. J Clin Oncol 28(29):3739-3746, 2011. PMID: 21900106.
53. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun B, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 117(12):2659-2667, 2011. PMID: 21656744.
54. Arun BK, Valero V, Liu D, Brewster AM, Green M, Gutierrez-Barerra A, Green M, Gutierrez-Barerra AM, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation pervention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res 5(2):276-82, 2011. PMID: 22102688.
55. Euhus DM, Bu D, Xie XJ, Sarode V, Ashfaq R, Hunt KK, Xia W, O'Shaughnessy JA, Grant M, Arun B, Dooley W, Miller A, Flockhart DA, Lewis C. Tamoxifen downregulates Ets-oncogene family members ETV4 and ETV5 in benign breast tissue: Implications for durable risk reduction. Cancer Prev Res 4(11):1852-1862, 2011. PMID: 21778330.
56. Ready K, Arun B. Clinical assessment of breast cancer risk based on family history. J Natl Compr Canc Netw 8(10):1148-55, 11/2010. PMID: 20971839.
57. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-8, 2010. PMID: 20054647.
58. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. A phase II trial of anastrozole plus goserelin in the treatment of hormone receptor positive, metastatic carcinoma of the breast in pre-menopausal women. J Clin Oncol 28(25):3917-3921, 2010. PMID: 20679610.
59. Rixe O, Franco S, Yardley D, Johnston S, Martin M, Arun B, Letrent S. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor canertinib (CI-1033) in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 64(6):1139-1148, 2010.
60. Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: Large and small trials. Semin Oncol 37(4):367-383, 2010. PMID: 20816507.
61. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer risk reduction. J Natl Compr Cancer Netw 8(10):1112-46, 2010. PMID: 20971838.
62. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models. Future Oncol 3(6):355-365, 2010. PMID: 20222793.
63. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-314, 2010. PMID: 19241157.
64. Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: A multi-center case-only analysis. Breast Cancer Res Treat 124(2):441-51, 2010. PMCID: PMC2925060.
65. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214-20, 2010. PMID: 20733129.
66. Cohen L, Chen Z, Arun B, Shao Z, Dryden M, Xu L, LePetross C, Dogan B, McKenna BJ, Markman M, Babiera G. External qigong therapy for women with breast cancer prior to surgery. Integrative Cancer Therapies 9(4):348-353, 2010.
67. Yi M, Hunt KK, Arun B, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 3(8):1026-1034, 2010. PMID: 20647335.
68. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-S-transferase-pi expression in early breast cancer: Association with outcome and response to chemotherapy. Cancer Invest 28(5):554-559, 2010. PMID: 20210524.
69. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun B, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479-487, 2010. PMID: 20431955.
70. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235-244, 2010. PMID: 20609467.
71. Perez A, Arun B, Tripathy D, Tagliaferri M, Shaw H, Kimmick G, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Wittes J, Shapiro C. Phase 1B dose escalation trial of scutellaria barbata (BZL 101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-118, 2010.
72. Zhang D, Tari AM, Akar U, Arun B, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser10 p27 phosphorylation in epidermal growth factor receptor-epressing beast cancer. Mol Cancer Ther 9(11):3090-9, 2010. PMCID: PMCPMC3062953.
73. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9(5):1180-1187, 2010. PMID: 20423989.
74. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun B, Wang LE. The funtional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat 122(1):243-249, 2010. PMCID: PMC2883663.
75. Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Nagendra HR, Wei Q, Cohen L. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol 8(2):43-55, 2010. PMID: 20388445.
76. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 115(4):725-730, 2009. PMID: 19127556.
77. Visvanathan K, Chlebowski, TR, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL Brown P, Cuzick J, Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235-3258, 2009.
78. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of pre-invasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res 2(2):122-7, 2009. PMID: 19174581.
79. Atchley D, Albarracin C, Lopez A, Valero V, Amos V, Gonzalez-Angulo A, Hortobagyi G, Arun B. Clinical and pathological characteristics of patients with BRCA-positive and BRCA-negative breast cancer. JCO 26(26):4282-8, 2008. PMID: 18779615.
80. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 14(1):62-8, 2008. PMID: 18303485.
81. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 2008. PMID: 18581139.
82. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun B, Hortobagyi GN. Ductal Carcinoma In Situ: State of the Science and Roadmap to Advance the Field. J Clin Oncol 27(2):279-88, 2008. PMID: 19064970.
83. Wang H, Arun B, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14(3):261-7, 2008. PMID: 18373644.
84. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun B, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 19(10):1713-9, 2008. PMID: 18515258.
85. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. PMID: 18776816.
86. Rivera E, Mejia J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Hortobagyi G, Valero V. Phase III study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455-61, 2008. PMID: 18300256.
87. Vogel K, Atchley DP, Erlichman J, Broglio K, Ready KR, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25(29):4635-41, 2007.
88. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi G, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13(16):4943-48, 2007. PMID: 17699874.
89. Yang WT, Dryden M, Broglio, K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111(3):405-10, 2007. PMID: 18026834.
90. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortonagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007. PMID: 17676585.
91. Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun B, Lovalvo JL, Eiseman IA, Olson SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12(14 Pt 1):4274-82, 2006. PMID: 16857802.
92. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107(12):2745-51, 2006. PMID: 17109443.
93. Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 14(7):1681-5, 2005. PMID: 16030101.
94. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun B, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 2005. PMID: 15738535.
95. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 2004. PMID: 15136595.
96. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21(18):3454-61, 2003. PMID: 12972520.

Grant & Contract Support

Title: Identification and characterization of variants of uncertain significance (VUS) in BRCA1 and BRCA2
Funding Source: Sister Institute Network Fund
Role: Principal Investigator
Duration: 1/26/2015 - 1/25/2017
 
Title: A model for individualized risk prediction of contralateral breast cancer
Funding Source: The University of Texas at Dallas
Role: Co-Investigator
Principal Investigator: Biswas
Duration: 9/1/2014 - 8/31/2016
 
Title: Increasing genetics services availability to underserved high risk breast cancer patients
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 4/1/2014 - 9/30/2015
 
Title: Education and expansion of breast cancer genetic services to underserved populations in the Greater Houston area.
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 4/1/2013 - 9/30/2015
 
Title: Genetic risk prediction in primary care
Funding Source: The University of Texas at Dallas
Role: Multi Principal Investigator (Clinical)
Principal Investigator: Biswas
Duration: 1/1/2013 - 12/31/2015
 
Title: Cancer prevention agent development program: Early phase clinical research consortium
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Brown
Duration: 9/24/2012 - 9/23/2017
 
Title: UT MD Anderson Cancer Center CCOP Research Base
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 4/10/2007 - 7/31/2015

Last updated: 5/13/2015